The ESHRE-ASRM 2021 congress focus the debate of specialists in the PGT-A, the non-invasive biopsy and double stimulation.

Among the relevant aspects addressed in the international congress in which European and American specialists participated, two stand out, on the one hand the PGT-A and on the other the double ovarian stimulation.

Instituto Bernabeu is a pioneer in the PGT-A analysis, the preimplantation genetic test to detect aneuploidies (chromosomal abnormalities) of the embryo, and the clinic remains at the forefront of research. At the same time, emphasizes the advancement of non-invasive PGT-A (niPGT-A) research, which means not having to biopsy the embryo and reduces the impact on implantation capacity. Specialists have addressed the pros and cons of this analysis.

This way, the genetic unit of the Instituto Bernabeu is at the forefront in the advancement of this analysis. In fact, it has carried out the first study that evaluates the consistency of different chromosome analysis techniques for niPGT-A.

When it comes to biopsy the embryo, the Institute Bernabeu’s position is always to do it in the blastocyst phase, on the fifth day of development, as it is less harmful than performed on the third day; and with the use of the next-generation sequencing (NGS) technique.

Also regarding double stimulation, the director of the low ovarian reserve unit highlights the avant-garde role of the studies and clinical trials carried out by Instituto Bernabeu.